Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Conclusions- Enrollment is ongoing to evaluate once weekly selinexor in combination with Pd , (SPd). This all-oral SPd combination has clinical activity with an ORR 55% in pom-naive pts with heavily pretreated MM compared to previously published data of 30% ORR for Pd alone. Similarly, the PFS on SPd is 10.3 months vs. <4 months for Pd alone. No unexpected adverse events were noted. Phase 1 dose escalation of the combination of SPd is ongoing to define the optimal RP2D.DisclosuresChen: Amgen: Honoraria. Sebag: Janssen Inc.: Membership on an entity's Board of Directors or advisory committees; Amgen Canada: Membership on an entity's Board of Directors or advisory committees; Takeda Canada: Membership on an entity's Board of Directors or advisory committees; Celgene Canada: Membership on an entity's Board of Directors or advisory committees. White: Amgen, Celgene, Janssen, Takeda: Honoraria. Bensinger: Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; amgen: Speakers Bureau. Gasparetto: Bristol-Myers Squibb: Consultancy, Honoraria, Other: Travel; Janssen: Consultancy, Honoraria, Other: Travel; Takeda: Honoraria; Celgene: Consultancy, Honoraria, Other: Travel, Research Funding. Leblanc: Amgen Canada: Membership on an entity's Board of Directors or advisory committees; Janssen Inc.: Membership on an entity's Board o...

Source: Blood - November 21, 2018 Category: Hematology Authors: Chen, C. I., Sutherland, H. J., Kotb, R., Sebag, M., White, D. J., Bensinger, W., Gasparetto, C. J., Leblanc, R., Venner, C. P., Lentzsch, S., Schiller, G. J., Lipe, B., Del Col, A., Shah, J. J., Jeha, J., Saint-Martin, J.-R., Kauffman, M. G., Shacham, S. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research